Last week had some wags wondering if Allergan CEO David Pyott might be forced into an error by spending too much on an acquisition in hopes of putting the Irvine-based drug maker out of reach of hostile pursuers Valeant Pharmaceuticals and New York hedge funder Bill Ackman...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to OCBJ.com archives
  • Book of Lists — the most comprehensive business resource in Orange County
  • NEW: Orange County 500 — influential business leaders you need to know
Yours for only $99